Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease
Barbara R Cardoso, Blaine R Roberts, Charles B Malpas, Lucy Vivash, Sila Genc, Michael M Saling, Patricia Desmond, Christopher Steward, Rodney J Hicks, Jason Callahan, Amy Brodtmann, Steven Collins, Stephen Macfarlane, Niall M Corcoran, Christopher M Hovens, Dennis Velakoulis, Terence J O'Brien, Dominic J Hare, Ashley I Bush
NEUROTHERAPEUTICS | SPRINGER | Published : 2019
Insufficient supply of selenium to antioxidant enzymes in the brain may contribute to Alzheimer's disease (AD) pathophysiology; therefore, oral supplementation may potentially slow neurodegeneration. We examined selenium and selenoproteins in serum and cerebrospinal fluid (CSF) from a dual-dose 24-week randomized controlled trial of sodium selenate in AD patients, to assess tolerability, and efficacy of selenate in modulating selenium concentration in the central nervous system (CNS). A pilot study of 40 AD cases was randomized to placebo, nutritional (0.32 mg sodium selenate, 3 times daily), or supranutritional (10 mg, 3 times daily) groups. We measured total selenium, selenoproteins, and i..View full abstract
Related Projects (2)
Awarded by Australian National Health and Medical Research Council
Funded by Fellowships from the Brazilian Government Science Without Borders program (Ciencia sem Fronteiras; BRC), Deakin University (BRC), and the Australian National Health and Medical Research Council (GNT1138673, BRR; GNT1105784, SC; GNT1122981, DJH; GNT1103703, AIB); a Program Grant from the Australian National Health and Medical Research Council (GNT1132604, AIB); and by Velacor Therapeutics. Agilent Technologies provided material and research support (BRR, DJH).